A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigator initiated study, single-blinded, parallel, randomized study will be conducted in subjects with 2 or more keloids similar in size and duration on a similar area of the body. The response of the closure techniques will be evaluated by clinical and instrumental assessments. Each qualified subject will be assessed and the keloids will be randomly assigned to the Clozex or suture closure. One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex. A second keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures. The inflammation index and the keloid recurrence rate at each surgical wound closure site will be compared.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168

Keloid

COMPLETED PHASE2

Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars

NCT01978301

Fibrosis

TERMINATED PHASE1

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

NCT00754247

Keloid Hypertrophic Scar Cicatrix, Hypertrophic

COMPLETED PHASE4

Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids

NCT04710719

Keloid Keloid Scar Following Surgery

COMPLETED NA

Study of Psycho-Social Impact of Keloid

NCT01478243

Keloid

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be undertaken to compare the efficacy of two closure techniques for excised keloids. (1) Clozex, a non-latex, hypoallergenic adhesive polymeric interlaced film designed to adhere to proximal wound edges for 7-10 days, will be used after the punch biopsy or excision of a keloid and (2) sutures to close a similar second keloid after the punch biopsy or excision of a keloid.

On day 12, the investigator and subject will assess the keloid site(s) with the use of a visual analog scale.

There is an optional follow-up at 3 months and 6 months to assess the recurrence of the keloid and the effectiveness of the treatments with a visual analog scale.

The subject will assess the keloid site(s) with the use of the following visual analog scale:

1. Cosmetic appearance
2. Pain
3. Tenderness
4. Itching
5. Oozing
6. Redness
7. Warmth

The investigator will assess the keloid site(s) with the use of this visual analog scale:

1. Global appearance
2. Color
3. Matte/Shiny
4. Contour
5. Distortion
6. Texture
7. Oozing
8. Redness
9. Warmth
10. Firmness

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keloid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suture

A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.

Group Type ACTIVE_COMPARATOR

Suture

Intervention Type PROCEDURE

One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.

Clozex

One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.

Group Type ACTIVE_COMPARATOR

Clozex

Intervention Type DEVICE

One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suture

One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.

Intervention Type PROCEDURE

Clozex

One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or females, in good health, and at least 12 years of age.
* Individuals with 2 or more keloids on the trunk, arm, leg, and neck between 0.5 and 2 cm in length.
* Individuals who are willing and able to participate in the requirements of the study, including signing the informed consent.
* In the opinion of the investigator, the 2 keloids can be excised in a similar manner and closed properly with the two techniques and will benefit from the procedure.
* In the opinion of the investigator, the keloid could benefit from surgical procedure.

Exclusion Criteria

* Individuals with keloids that do not fit into the criteria.
* Individuals who are planning pregnancy, pregnant, or breast feeding.
* Individuals with a history of medical or dermatologic conditions which, in the opinion of the investigator, would put the subject at heightened risk or would limit complicate the study evaluations required by the protocol.
* Individuals who present with excessive body hair in the designed keloid area.
* Individuals with uncontrolled diabetes.
* Individuals with autoimmune disorders (HIV/AIDs, SLE).
* Subjects who have received keloid treatment within one month of the first day of the study.
* Individuals who plan to receive keloid treatment(s) during the study.
* Individuals who are currently taking prescription or over the counter medication or interventions on a regular basis that as part of their mechanism of action, have the potential to mask an inflammatory reaction. Examples of such medications include, but are not limited to, corticosteroids, non-steroid anti-inflammatory drugs (NSAIDs), antihistamines, aspirin (81mg or less daily dosage permissible), or other medications that in the opinion of the investigator or designee may expose the subject to heightened risk or complicate the study assessments.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No